Talpaz; Moshe

Patent Applications and Registrations

Patent applications and USPTO patent grants for Talpaz; Moshe.The latest application filed is for "deubiquitinase inhibitors and methods for use of the same".

Company Profile

0.11.14

Talpaz; Moshe - Ann Arbor MI
Talpaz; Moshe - Houston TX

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Deubiquitinase inhibitors and methods for use of the same Grant 9,868,736 - Donato , et al. January 16, 2	2018-01-16
Deubiquitinase Inhibitors And Methods For Use Of The Same App 20160237082 - Donato; Nicholas J. ; et al.	2016-08-18
Compounds for treatment of cell proliferative diseases Grant 9,096,499 - Priebe , et al. August 4, 2	2015-08-04
Deubiquitinase Inhibitors and Methods for Use of the Same App 20140357673 - Donato; Nicholas J. ; et al.	2014-12-04
Compounds For Treatment Of Cell Proliferative Diseases App 20140329901 - PRIEBE; Waldemar ; et al.	2014-11-06
Deubiquitinase inhibitors and methods for use of the same Grant 8,809,377 - Donato , et al. August 19, 2	2014-08-19
Compounds for treatment of cell proliferative diseases Grant 8,648,102 - Priebe , et al. February 11, 2	2014-02-11
Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia Grant 8,268,837 - Donato , et al. September 18, 2	2012-09-18
Compounds For Treatment Of Cell Proliferative Diseases App 20120214850 - Priebe; Waldemar ; et al.	2012-08-23
Deubiquitinase Inhibitors and Methods for Use of the Same App 20120077806 - Donato; Nicholas J. ; et al.	2012-03-29
Compounds for treatment of cell proliferative diseases Grant 8,119,827 - Priebe , et al. February 21, 2	2012-02-21
Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia Grant 8,119,649 - Donato , et al. February 21, 2	2012-02-21
Compounds For Treatment Of Cell Proliferative Diseases App 20110021805 - Priebe; Waldemar ; et al.	2011-01-27
Tryphostin-analogs For The Treatment Of Cell Proliferative Diseases App 20100292229 - Donato; Nicholas J ; et al.	2010-11-18
Compounds for treatment of cell proliferative diseases Grant 7,745,468 - Priebe , et al. June 29, 2	2010-06-29
Use Of C-src Inhibitors Alone Or In Combination With Sti571 For The Treatment Of Leukaemia App 20090227608 - Donato; Nicholas J. ; et al.	2009-09-10
Inhibition of osteolytic lesions by SRC kinase inhibitors Grant 7,468,379 - Darnay , et al. December 23, 2	2008-12-23
Use Of C-src Inhibitors Alone Or In Combination With Sti571 For The Treatment Of Leukaemia App 20070149539 - Donato; Nicholas J. ; et al.	2007-06-28
Use of c-Src inhibitors alone or in combinaton with STI571 for the treatment of leukaemia App 20070027167 - Donato; Nicholas J. ; et al.	2007-02-01
Inhibition of osteolytic lesions by SRC kinase inhibitors App 20070004748 - Darnay; Bryant G. ; et al.	2007-01-04
Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia App 20060074094 - Donato; Nicholas J. ; et al.	2006-04-06
Compounds for treatment of cell proliferative diseases App 20050277680 - Priebe, Waldemar ; et al.	2005-12-15
Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia App 20040248906 - Donato, Nicholas J ; et al.	2004-12-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.